Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

Next Previous
Trial Profile

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Venetoclax (Primary) ; Ziftomenib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KOMET-007
  • Sponsors Kura Oncology

Most Recent Events

  • 14 May 2025 According to a Kura Oncology media release, the company announced that an abstract highlighting clinical data from the KOMET-007 has been accepted for presentation at the upcoming 2025 European Hematology Association (EHA) Congress, to be held in Milan, Italy, from June 12-15, 2025.
  • 01 May 2025 According to a Kura Oncology media release, company to present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with intensive chemotherapy (7+3) in the frontline setting at EHA in the second quarter of 2025 and at a medical meeting in the second half of 2025.
  • 05 Feb 2025 According to a Kura Oncology media release, data from ziftomenib in combination with 7+3 in newly diagnosed NPM1-m AML and KMT2A-r AML expected in second quarter of 2025 and ziftomenib in combination with venetoclax / azacitidine in NPM1-m AML in second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top